KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Convertible Debt (2016 - 2022)

Supernus Pharmaceuticals (SUPN) has disclosed Convertible Debt for 10 consecutive years, with $400.4 million as the latest value for Q1 2022.

  • On a quarterly basis, Convertible Debt rose 9.38% to $400.4 million in Q1 2022 year-over-year; TTM through Mar 2022 was $400.4 million, a 9.38% increase, with the full-year FY2021 number at $379.3 million, up 4.84% from a year prior.
  • Convertible Debt was $400.4 million for Q1 2022 at Supernus Pharmaceuticals, up from $379.3 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $400.4 million in Q1 2022 to a low of $318.2 million in Q1 2018.
  • A 5-year average of $350.9 million and a median of $349.2 million in 2020 define the central range for Convertible Debt.
  • Peak YoY movement for Convertible Debt: soared 21769.57% in 2018, then grew 4.74% in 2019.
  • Supernus Pharmaceuticals' Convertible Debt stood at $329.5 million in 2018, then rose by 4.77% to $345.2 million in 2019, then grew by 4.8% to $361.8 million in 2020, then increased by 4.84% to $379.3 million in 2021, then grew by 5.57% to $400.4 million in 2022.
  • Per Business Quant, the three most recent readings for SUPN's Convertible Debt are $400.4 million (Q1 2022), $379.3 million (Q4 2021), and $374.8 million (Q3 2021).